Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).

Add to Collection

2018 Aug Others MS Kuchay, S Krishan, SK Mishra, KJ Farooqui… - Diabetes …, 2018 - Am Diabetes Assoc 102

Full Author : ['Kuchay, Mohammad Shafi', 'Krishan, Sonal', 'Mishra, Sunil Kumar', 'Farooqui, Khalid Jamal', 'Singh, Manish Kumar', 'Wasir, Jasjeet Singh', 'Bansal, Beena', 'Kaur, Parjeet', 'Jevalikar, Ganesh', 'Gill, Harmendeep Kaur', 'Choudhary, Narendra Singh', 'Mithal, Ambrish']
Journal Title : Diabetes care
Chapter : Section3
Journal Year : 2018
Cited by : 410.0

OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat are scarce. This study examined the effect of empagliflozin (an SGLT-2 in..... Read More

Keywords : ["randomized control trial elift trial", "nonalcoholic fatty liver disease", "liver fat", "type diabetes", "patient", "empagliflozin", "effect"]
PubMed Link : https://diabetesjournals.org/care/article-abstract/41/8/1801/36391
Google Scholar Link : https://scholar.google.com/scholar?cites=10902569215125252838&as_sdt=40005&sciodt=0,10&hl=en&num=20

Have a Question?

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).